Amoxicillin is indicated for the treatment of the following infections in adults and children (see section 4.2, 4.4 and 5.1). • Acute bacterial sinusitis • Acute streptococcal tonsillitis and pharyngitis • Acute exacerbations of chronic bronchitis • Community acquired pneumonia • Acute otitis media • Acute cystitis • Acute pyelonephritis • Asymptomatic Bacteriuria in pregnancy • Typhoid and paratyphoid fevers • Dental abscess with spreading cellulitis • Prosthetic joint infections • Helicobacter pylori eradication • Lyme disease Amoxicillin is also indicated for the prophylaxis of endocarditis. Consideration should be given to official guidance on the appropriate use of antibacterial agents. The dose of Amoxicillin that is selected to treat an individual infection should take into account: • The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4) • The severity and the site of infection • The age, weight and renal function of the patient; as shown below The duration of therapy should be determined by the type of infection and the response of the patient, and should generally be as short as possible. Some infections require longer periods of treatment (see section 4.4 regarding prolonged therapy). Children may be treated with Amoxicillin capsules, dispersible tablets, suspensions or sachets. Amoxicillin Paediatric Suspension is recommended for children under six months of age. Therapy can be started parenterally according to the dosing recommendations of the intravenous formulation and continued with an oral preparation. Hypersensitivity to the active substance, to any of the penicillins or to any of the excipients listed in section 6.1. Before initiating therapy with amoxicillin, careful enquiry should be made concerning previous hypersensitivity reactions to penicillin and cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8). At any given time, more than 10 million women in the United States are pregnant or lactating, and exposing a fetus or newborn to antibiotics can pose a unique threat. Changes during pregnancy and lactation also can trigger pharmacokinetic and pharmacodynamic modifications that alter the effectiveness of antibiotics. Nahum and colleagues reviewed the literature on antibiotic use to provide updated, evidence-based information on antibiotic use in women who are pregnant or lactating. The researchers examined published medical literature, sources on teratogenicity and prescribing for women who are lactating or pregnant, and they abstracted data from product labels for drugs approved by the U. Food and Drug Administration (FDA) for use during pregnancy. The authors identified 124 references that covered 11 commonly prescribed antibiotics, all of which cross the placenta and are excreted in human breast milk. There was no teratogenic potential for penicillins G and V potassium (V-Cillink); unlikely potential for amoxicillin, chloramphenicol (Chloromycetin), ciprofloxacin (Cipro), doxycycline (Vibramycin), levofloxacin (Levaquin), and rifampin (Rifadin); and undetermined potential for clindamycin (Cleocin), vancomycin, and gentamicin. All agents were FDA Pregnancy Category B (amoxicillin, clindamycin, penicillin G, penicillin V potassium, and vancomycin) or C (chloramphenicol, ciprofloxacin, gentamicin, levofloxacin, and rifampin), except for doxycycline, which was category D.
While there are no controlled studies of amoxicillin use in pregnant women to show safety, an expert review of published data on experiences. Amoxicillin is an antibiotic often used for the treatment of a number of bacterial infections. It may be used for middle ear infection, strep throat. Its use in pregnancy and breastfeeding does not appear to be harmful. Amoxicillin is in the beta-lactam family of antibiotics.